The therapeutic options available today allow the choice of an individualized therapeutic strategy. In addition to covventional immunosuppressants, biologics are becoming increasingly important. Belimumab has been approved as an add-on to standard therapy for several years. Based on current clinical data, there is a good chance that additional monoclonal antibodies could come to market in the near future and complement the arsenal of targeted therapies.